



Summary of NICE Guidelines

| | |
|--|---|
| Title | Inflammatory Bowel Disease |
| NICE Reference | QS81 |
| Date of Review: | January 2018 |
| Date of Publication | February 2015 |
| Summary of Guidance (Max 250 words) | <p style="text-align: center;">Quality statements</p> <p><u>Statement 1.</u> <i>People with suspected inflammatory bowel disease (IBD) have a specialist assessment within 4 weeks of referral.</i></p> <p>Persons with lower GI symptoms of 6 weeks duration should be suspected of having IBD. Local referral pathways should be in place so patients with suspected IBD are seen quickly to prevent a delay in diagnosis and enable treatment options. Specialist assessment may include laboratory tests and /or endoscopy.</p> <p><u>Statement 2.</u> <i>Services provide age-appropriate support from a multidisciplinary team for people with inflammatory bowel disease, and their family members or carers.</i></p> <p>The emotional, psychological and social impact of IBD on a person, and their support needs, will vary with age. Age-appropriate support should be received from a multi-disciplinary team including nurses, doctors, dieticians and pharmacists.</p> <p><u>Statement 3.</u> <i>People having surgery for inflammatory bowel disease have it undertaken by a colorectal surgeon who is a core member of the inflammatory bowel disease multidisciplinary team.</i></p> <p>A surgeon specialising in IBD will be better equipped to make informed decisions regarding the need and timing of surgery. The likelihood that surgery is a success will also be improved when performed by a specialist surgeon.</p> <p><u>Statement 4.</u> <i>People receiving drug treatment for inflammatory bowel disease are monitored for adverse effects.</i></p> <p>Local safety policies and procedures should be in place to monitor the impact of treatment on the patient, with regular check-ups to assess for any side effects. The BNF should be used to inform the monitoring required (including blood tests) for specific drugs.</p> |

| | |
|---|--|
| Impact on Lab (See below) | <input checked="" type="checkbox"/> Moderate – Clinical scientists/chemical pathologist may be involved in preparation of locally agreed guidelines/pathways for 1) referral of patients to IBD specialists and ii) monitoring of IBD treatment. |
| Lab professionals to be made aware | <input type="checkbox"/> Chemical Pathologist <input type="checkbox"/> Clinical Scientist |
| Please detail the impact of this guideline (Max 150 words) | QS81 is a quality standard aimed at improving patient experience and quality of life of persons with IBD. It does not cover laboratory tests used to monitor patients or to investigating suspected IBD. |

Impact on Lab

- None:** This NICE guideline has no impact on the provision of laboratory services
- Moderate:** This NICE guideline has information that is of relevance to our pathology service and may require review of our current service provision.
- Important:** This NICE guideline is of direct relevance to our pathology service and will have a direct impact on one or more of the services that we currently offer.

Written by: Helen Holt

Reviewed by: David Housley